Table 3.
Low risk (RS < 18) | Intermediate risk (RS 18–30) | High risk (RS ≥ 31) | Log rank, p | |
---|---|---|---|---|
Median TTP, months | ||||
All patients (n = 101) | NR (16–NR) | 22 (16–NR) | 16 (9–25) | 0.010 |
ER positive (n = 85) | 32 (16–NR) | 22 (16–NR) | 15 (9–25) | 0.007 |
ER positive/HER2 negative (n = 69) | NR (16–NR) | 20 (16–NR) | 15 (8–27) | 0.003 |
2-Year overall survival, % | ||||
All patients (n = 101) | 100 (78–100) | 100 (78–100) | 80 (69–93) | 0.035 |
ER positive (n = 85) | 100 (78–100) | 100 (78–100) | 77 (64–94) | 0.008 |
ER positive/HER2 negative (n = 69) | 100 (78–100) | 100 (75–100) | 69 (51–93) | < 0.001 |
Abbreviations: RS, recurrence score; NR, not reached; ER, estrogen receptor.